Phase 2 Melanoma Trial, Recruiting NCT06767306 Sponsor: Melanoma Institute Australia Condition: Melanoma
Back to Melanoma

Phase 2 Melanoma Trial, Recruiting

NCT06767306
Recruiting Phase 2 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older (male or female)
  • You are willing to sign a consent form agreeing to take part
  • Your doctors expect you to live for more than 6 months
  • You have been newly diagnosed with advanced (Stage IV) melanoma that started in the skin, on the hands or feet (acral), or from an unknown location, confirmed by a tissue biopsy
  • Your melanoma has spread to between 1 and 5 spots outside the brain, seen on CT and PET-CT scans, and cannot be removed by surgery
  • You may also have the original melanoma site and/or up to 4 nearby skin spread spots, as long as the total number of spots does not exceed 5
  • If you had surgery to relieve urgent symptoms (such as a bowel blockage), you may still qualify as long as no more than one spot was removed and 5 or fewer spots remain
  • At least one of your cancer spots can be measured on scans using standard measurement guidelines
  • There is no sign of melanoma spread to the brain (checked by MRI, or CT scan if MRI is not suitable for you)
  • All of your cancer spots can be treated with a precise, high-dose form of targeted radiation therapy (SBRT) at the required dose level
  • Your specialist doctor has decided you are well enough to receive immunotherapy treatment
  • Your general health and ability to carry out daily activities meets a standard score of 0–2 (meaning you are fully active to capable of basic self-care) (confirm with trial site)
  • If you could become pregnant, you must have a negative blood pregnancy test within 7 days of being assigned to a treatment group

Who may not be able to join:

  • Your melanoma started in the eye or on the mucous membranes (such as inside the mouth or nose)
  • You have serious or unstable health conditions that could affect your safety or ability to participate
  • You need radiotherapy urgently and immediately for a serious complication (such as pressure on the spinal cord or rapidly worsening symptoms)
  • You have previously had radiotherapy for Stage IV (advanced/spread) melanoma
  • Not all of your cancer spots can be safely treated with the targeted radiation therapy (SBRT), as decided by your radiation specialist
  • You have previously had drug treatment (such as chemotherapy or immunotherapy) for melanoma, unless it was given as a preventative treatment at an earlier, less advanced stage
  • You have any reason why you cannot safely receive the planned immunotherapy drugs
  • You have melanoma that has spread to the liver AND you have moderate or severe liver problems
  • You have a history of another cancer, unless you have been cancer-free for at least 1 year, have been fully treated, and have a low chance of it coming back
  • You are currently pregnant or breastfeeding

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 15 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Angela Hong, Melanoma Institute Australia

Phone: +61 2 9911 7296

Australian sites

Westmead Hospital, Westmead, New South Wales
Melanoma Institute Australia, Wollstonecraft, New South Wales
+612 9911 7200
Princess Alexandra Hospital, Woolloongabba, Queensland
The Alfred Hospital, Melbourne, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Melanoma Institute Australia
Registry
ClinicalTrials.gov
Start date
6 March 2025
Est. completion
1 April 2033

Where this trial is recruiting

🇦🇺 Australia 🇨🇦 Canada

4 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Overall survival

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 15 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov